drugset / Trial / NCT07832227
Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
Phase 2
Not yet recruiting
60 enrolled
Dana-Farber Cancer Institute
Eli Lilly and Company · collabKaryopharm Therapeutics Inc · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2, interventional treatment trial evaluating imlunestrant, abemaciclib, and selinexor in two separate patient cohorts: low grade serous ovarian cancer and endometrioid endometrial cancer. The study is non-randomized and open-label. Treatment is administered in the outpatient setting, with a 14-day Cycle 0 followed by 28-day treatment cycles.
Timeline
- Start
- 2026-12-01
- Primary completion
- 2028-12-01
- Completion
- 2029-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Imlunestrant | Small molecule | — | Oral |
| Subject | Selinexor | Other / unclassified | — | Oral |